COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs

被引：118
作者：
Warner, Timothy D. [1 ]
Mitchell, Jane A. [2 ]
机构：
[1] Barts & London, Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England
[2] Imperial Coll Sch Med, Royal Brompton Hosp, Unit Crit Care Med, London, England
来源：
LANCET | 2008年 / 371卷 / 9608期
基金：
英国惠康基金;
关键词：
D O I：
10.1016/S0140-6736(08)60137-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：270 / 273
页数：4
相关论文
共 22 条
[1]   Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association [J].
Antman, Elliott M. ;
Bennett, Joel S. ;
Daugherty, Alan ;
Furberg, Curt ;
Roberts, Harold ;
Taubert, Kathryn A. .
CIRCULATION, 2007, 115 (12) :1634-1642
[2]  
CRONBERG S, 1984, SCAND J HAEMATOL, V33, P155
[3]   Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib [J].
Farkouh, M. E. ;
Greenberg, J. D. ;
Jeger, R. V. ;
Ramanathan, K. ;
Verheugt, F. W. A. ;
Chesebro, J. H. ;
Kirshner, H. ;
Hochman, J. S. ;
Lay, C. L. ;
Ruland, S. ;
Mellein, B. ;
Matchaba, P. T. ;
Fuster, V. ;
Abramson, S. B. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (06) :764-770
[4]   Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial [J].
Farkouh, ME ;
Kirshner, H ;
Harrington, RA ;
Ruland, S ;
Verheugt, FW ;
Schnitzer, T ;
Burmester, GR ;
Mysler, E ;
Hochberg, MC ;
Doherty, M ;
Ehrsam, E ;
Gitton, X ;
Krammer, G ;
Mellein, B ;
Gimona, A ;
Matchaba, P ;
Hawkey, CJ ;
Chesebro, JH .
LANCET, 2004, 364 (9435) :675-684
[5]   Balancing prostanoid activity in the human vascular system [J].
Flavahan, Nicholas A. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (03) :106-110
[6]   Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study [J].
Graham, DJ ;
Campen, D ;
Hui, R ;
Spence, M ;
Cheetham, C ;
Levy, G ;
Shoor, S ;
Graham, D .
LANCET, 2005, 365 (9458) :475-481
[7]   Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities [J].
Grosser, T ;
Fries, S ;
FitzGerald, GA .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :4-15
[8]   The pharmacology of selective inhibition of COX-2 [J].
Grosser, Tilo .
THROMBOSIS AND HAEMOSTASIS, 2006, 96 (04) :393-400
[9]   NSAIDs, coxibs, and the intestine [J].
Hawkey, C. J. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 47 :S72-S75
[10]   Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis [J].
Henry, D ;
Lim, LLY ;
Rodriguez, LAG ;
Gutthann, SP ;
Carson, JL ;
Griffin, M ;
Savage, R ;
Logan, R ;
Moride, Y ;
Hawkey, C ;
Hill, S ;
Fries, JT .
BRITISH MEDICAL JOURNAL, 1996, 312 (7046) :1563-1566
123